Rezolute initiates phase 3 clinical study for rz358 in congenital hyperinsulinism

Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025

RZLT Ratings Summary

RZLT Quant Ranking